Inovio Pharmaceuticals Will Independently Develop Prostate Cancer Immunotherapy

Inovio Pharmaceuticals Will Independently Develop Prostate Cancer Immunotherapy
Inovio Pharmaceuticals, Inc. has announced that it has finished a 2013 licensing agreement with Roche to co-develop INO-5150, Inovio’s investigational drug targeting prostate cancer. Furthermore, both companies will no longer collaborate in prostate cancer research. Importantly, all the rights that Roche held towards INO-5150 will be returned to Inovio, which will independently continue with a Phase

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *